ADRX earnings analysis
10-Q · Filed November 12, 2026 · Our reading of the company's report
The latest report
ADARx reported third-quarter revenue of $2.217 million and EPS of $(1.74), while the nine-month net loss increased to $76.5 million from $51.5 million a year earlier. The balance sheet was strengthened by approximately…
Read full summary
ADARx reported third-quarter revenue of $2.217 million and EPS of $(1.74), while the nine-month net loss increased to $76.5 million from $51.5 million a year earlier. The balance sheet was strengthened by approximately $469.7 million of IPO net proceeds and $89.3 million of AbbVie private-placement gross proceeds, leaving $901.0 million in cash, cash equivalents and short-term investments and an expected runway into 2030. However, the company remains pre-commercial with three clinical programs, substantial ongoing losses, and heightened clinical, regulatory, China supply-chain, cybersecurity and dilution risks.
Reported figures
- Earnings per share
- $-1.74
What stood out
-
Collaboration revenue increased
Third-quarter revenue was $2.217 million. Collaboration revenue increased year over year, although the filing excerpt does not provide a separate collaboration-revenue amount.
-
Cash runway extends into 2030
Cash, cash equivalents and short-term investments totaled $901.0 million at September 30, 2026. Including approximately $62.3 million of October proceeds, management expects funding to support operations into 2030.
-
Substantial financing completed
The IPO generated approximately $469.7 million of net proceeds, including the underwriters’ option shares, while the AbbVie private placement generated approximately $89.3 million of gross proceeds.
-
Pipeline has three clinical programs
The company has three therapeutic candidates in clinical development—agazisiran, onvuzosiran and ADX-626—and two advanced preclinical programs.
What to watch
-
Losses continue to accelerate
The nine-month net loss increased to $76.5 million from $51.5 million in the prior-year period, and accumulated deficit reached $297.2 million as of September 30, 2026. Management expects significant operating losses and negative cash flows for the foreseeable future.
-
Cash runway depends on assumptions
Although the company reported $901.0 million of cash, cash equivalents and short-term investments, management cautioned that the runway-to-2030 estimate depends on assumptions that may prove incorrect and that capital could be consumed significantly faster than expected.
-
China supply-chain restrictions
The filing expands exposure to China-related supply-chain and regulatory restrictions: transitioning manufacturing or other activities away from an affected supplier could take 9 to 12 months or longer. The company states that some manufacturers, suppliers and service providers are located in China.
-
Expanded privacy and cyber risk
The filing adds detailed data-privacy and cybersecurity exposure, including potential NIS2 fines of at least €10 million or 2% of worldwide annual turnover for entities classified as essential, and at least €7 million or 1.4% for entities classified as important.
-
Potential dilution and share overhang
Post-IPO dilution and selling-pressure risk is material: holders of 70,904,025 shares have specified registration rights, while the 2026 Plan may automatically increase reserved shares by 5% of outstanding capital stock annually from January 1, 2027 through January 1, 2036.
-
Clinical and regulatory execution risk
Clinical and regulatory execution remains highly uncertain: the company has three candidates in clinical development but has never completed a pivotal clinical trial or submitted an NDA, and it relies on third parties for clinical trials and manufacturing.
Management's outlook
No numeric revenue or EPS guidance was provided. Management stated that cash, cash equivalents and short-term investments of $901.0 million as of September 30, 2026, together with approximately $62.3 million of October net proceeds, are expected to fund projected operating expenses and capital expenditures into 2030.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
See every ADRX trade live.
The free pages stop at the last full session. Trader shows every trade as it prints.